Thus, the TIDE algorithm showed that patients with CAF-risk bladder cancer were more likely to be unresponsive to anti-PD1 and anti-CTLA4 therapies in both the training and test groups. This evidence concerns the gene CTLA4 and urinary bladder cancer.